Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$3.63 - $6.06 $907,500 - $1.52 Million
-250,000 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$4.93 - $8.93 $1.23 Million - $2.23 Million
250,000
250,000 $2.05 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $136M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Abingworth LLP Portfolio

Follow Abingworth LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

News

Stay updated on Abingworth LLP with notifications on news.